Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride
Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride · Investor's Business Daily

In This Article:

Shares of Janux Therapeutics skyrocketed Tuesday on "unprecedented" results for an experimental prostate cancer treatment.